132 related articles for article (PubMed ID: 8822584)
1. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis.
Mesters RM; Flörke N; Ostermann H; Kienast J
Thromb Haemost; 1996 Jun; 75(6):902-7. PubMed ID: 8822584
[TBL] [Abstract][Full Text] [Related]
2. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
[TBL] [Abstract][Full Text] [Related]
3. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.
Raaphorst J; Johan Groeneveld AB; Bossink AW; Erik Hack C
Thromb Haemost; 2001 Aug; 86(2):543-9. PubMed ID: 11522001
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
[TBL] [Abstract][Full Text] [Related]
5. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.
Mesters RM; Mannucci PM; Coppola R; Keller T; Ostermann H; Kienast J
Blood; 1996 Aug; 88(3):881-6. PubMed ID: 8704245
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock.
Pralong G; Calandra T; Glauser MP; Schellekens J; Verhoef J; Bachmann F; Kruithof EK
Thromb Haemost; 1989 Jun; 61(3):459-62. PubMed ID: 2678584
[TBL] [Abstract][Full Text] [Related]
7. Tight glycemic control may favor fibrinolysis in patients with sepsis.
Savioli M; Cugno M; Polli F; Taccone P; Bellani G; Spanu P; Pesenti A; Iapichino G; Gattinoni L
Crit Care Med; 2009 Feb; 37(2):424-31. PubMed ID: 19114908
[TBL] [Abstract][Full Text] [Related]
8. TAFI and PAI-1 levels in human sepsis.
Zeerleder S; Schroeder V; Hack CE; Kohler HP; Wuillemin WA
Thromb Res; 2006; 118(2):205-12. PubMed ID: 16009400
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen: an important hemostatic parameter in septic patients.
Duboscq C; Quintana I; Bassilotta E; Bergonzelli GE; Porterie P; Sassetti B; Haedo AS; Wainsztein N; Kruithof EK; Kordich L
Thromb Haemost; 1997 Jun; 77(6):1090-5. PubMed ID: 9241738
[TBL] [Abstract][Full Text] [Related]
10. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients.
Voves C; Wuillemin WA; Zeerleder S
Blood Coagul Fibrinolysis; 2006 Sep; 17(6):445-51. PubMed ID: 16905947
[TBL] [Abstract][Full Text] [Related]
11. The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure.
Green J; Doughty L; Kaplan SS; Sasser H; Carcillo JA
Thromb Haemost; 2002 Feb; 87(2):218-23. PubMed ID: 11858480
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of plasminogen activator in neutrophils and mononuclear cells from septic patients.
Haj MA; Robbie LA; Adey GD; Bennett B
Thromb Haemost; 1995 Dec; 74(6):1528-32. PubMed ID: 8772232
[TBL] [Abstract][Full Text] [Related]
13. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
15. Elevated nucleosome levels in systemic inflammation and sepsis.
Zeerleder S; Zwart B; Wuillemin WA; Aarden LA; Groeneveld AB; Caliezi C; van Nieuwenhuijze AE; van Mierlo GJ; Eerenberg AJ; Lämmle B; Hack CE
Crit Care Med; 2003 Jul; 31(7):1947-51. PubMed ID: 12847387
[TBL] [Abstract][Full Text] [Related]
16. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
17. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
18. Vitamin E improves fibrinolytic activity in patients with coronary spastic angina.
Miyamoto S; Kawano H; Takazoe K; Soejima H; Sakamoto T; Hokamaki J; Yoshimura M; Nakamura H; Yodoi J; Ogawa H
Thromb Res; 2004; 113(6):345-51. PubMed ID: 15226088
[TBL] [Abstract][Full Text] [Related]
19. Comparative short-term prognostic value of hemostatic and inflammatory markers in patients with non-ST elevation acute coronary syndromes.
Passoni F; Morelli B; Seveso G; Lazzati L; Beria G; Del Rosso G; D'Urbano M; Cafiero F; Mariani G; De Servi S
Ital Heart J; 2002 Jan; 3(1):28-33. PubMed ID: 11899586
[TBL] [Abstract][Full Text] [Related]
20. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Agren A; Wiman B; Schulman S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
